Exclusive: National Vision’s CEO on transformation, margins, and growth By Investing.com

Shares are up roughly 120% over the past 12 months as National Vision shifts toward managed‑care customers, which now represent ~42% of sales. Operating margins expanded 160 bps year‑over‑year in fiscal 2025 and Q4 gross margin rose ~40 bps; management forecasts another 50–150 bps of operating margin improvement between 2026–2030 as premium frames reach 60% of assortment by end‑2026. Strategic drivers include a successful Ray‑Ban Meta smart‑eyewear rollout (to 1,200+ locations), rising premium lens attach rates, technology investments, and a modest store opening plan of 30–35 new locations this year with bigger expansion targeted for 2028.

Analysis

National Vision’s strategy is a classic mix-shift play: trading higher foot-traffic elasticity for higher-ticket, higher-lifetime-value customers while leaning on tech and product mix to recover margin dollars. The non-obvious lever is throughput per exam — incremental managed-care and premium-lens transactions should amplify same-store revenue with modest incremental labor, meaning operating leverage can rise faster than headline gross-margin rates imply. Smart-eyewear and premium-frame penetration create a two-way supply effect: they lift average ticket and attach rates but expose the company to vendor concentration, fulfillment/lab capacity, and promotional dynamics that can introduce lumpy margin volatility. Finally, the near-term story (quarters) is execution and sell-through on smart products; the medium-term (18–36 months) hinge is whether technology investments convert into higher exams-per-store and lower customer acquisition cost; the long-term (3–5 years) payoff is faster store roll‑out and potential capture of new tech partnerships.

Key Decisions for Investors

• Long EYE shares (core 12–24 month holding). Entry: on <8–12% pullback from today or into next quarterly report if sell‑side expectations miss on SG&A cadence. Risk management: size to 3–5% of equity sleeve, tighten if premium-lens attach rates or smart-eyewear sell‑through underperform; reward: asymmetric upside if operating margin trajectory continues and store expansion accelerates in 2028.
• Buy EYE 12–18 month call spread (debit-limited) to play multi-year margin expansion while capping premium decay risk. Structure example: long 18‑month ATM calls, sell a higher strike to fund ~30–50% of cost. R/R: limited downside to premium paid, target 2.5–3x payoff if EBITDA margin improves per management roadmap.
• Pair trade: long EYE / short WRBY (Warby Parker) 6–12 month pair to exploit model divergence — EYE benefits from managed-care network access and higher attach rates while WRBY is more exposed to DTC traffic and discretionary frame cyclicality. Size neutral to beta; exit on convergence of forward EBIT multiples or if both retail comps show synchronized sell‑through weakness.
• Watch-list catalysts and stop triggers: confirm (1) sustained premium-lens attach-rate improvement for two consecutive quarters, (2) consistent smart-eyewear ASP and sell-through data, and (3) capex cadence that supports lab capacity; if any catalyst fails, trim positions and consider hedging with short XRT exposure for 3–6 months.